Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, talks about individualized treatment and delivering the right treatment for the right patient in chronic lymphocytic leukemia (CLL). Prof. Stilgenbauer explains that we are now on the road towards individualized treatment. There is data available from genome wide sequencing (GWS) studies that really help identify the landscape of CLL cancer driver mutations. Prof. Stilgenbauer mentions bringing this into clinical trials in the light of the novel agents, to identify the particular subgroups that benefit best from a particular given treatment. Prof. Stilgenbauer is optimistic that the coming months will bring new, exciting findings in this direction. He finishes off with the mention that we are on a good track to link the biology of the disease to the biological treatments available now. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.